Results 21 to 30 of about 267,125 (312)

Personalised medicine in interstitial lung diseases

European Respiratory Review, 2018
Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised ...
Maria A. Kokosi, George A. Margaritopoulos, Athol U. Wells   +2 more
doaj   +1 more source

Airway involvement in interstitial lung disease [PDF]

, 2006
PURPOSE OF REVIEW: After briefly discussing several ways to approach airway involvement in interstitial lung diseases - by diagnostic methodologies used to assess it, considering different topographical involvement, related to its presence in the diffuse
Robalo-Cordeiro, C
core   +1 more source

MRI of the lung (3/3)-current applications and future perspectives [PDF]

, 2011
BACKGROUND: MRI of the lung is recommended in a number of clinical indications. Having a non-radiation alternative is particularly attractive in children and young subjects, or pregnant women.
A Hebestreit, A Kluge, A Kluge, A Kluge, AA Bankier, AC Henderson, AS Brody, BJ Pichler, BJ Pichler, C Fink, C Hintze, C Hintze, C Rieger, CA Yi, CA Yi, CP Heussel, DM Mannino, F Molinari, F Risse, F Santamaria, G Antoch, G Antoch, G Bauman, G Bauman, G Lutterbey, G Lutterbey, G Sergiacomi, H Hatabu, H Zaidi, HF Wehrl, HK Song, HK Song, IL Theissen, J Biederer, J Biederer, J Biederer, J Biederer, J Biederer, J Biederer, J Biederer, J Ley-Zaporozhan, J Ley-Zaporozhan, JC Hogg, K Cederlund, K Sandek, K Suga, K Suga, LP Qi, M Bhalla, M Decramer, M Eichinger, M Gaeta, M Oudkerk, M Puderbach, M Puderbach, M Puderbach, M Puderbach, M Stern, M Wagner, MD Cohen, ND Abolmaali, NJ Morrison, NL Müller, O Ratib, PA Jong de, PA Jong de, PD Stein, PD Stein, R Eibel, R Failo, RE Jacob, RG McFadden, RJ Theilmann, RL Gibson, S Akata, S Montella, S Pauls, SK Alford, T Amundsen, T Iwasawa, T Iwasawa, T Iwasawa, T Mori, T Rupprecht, TA Kuder, TH Helbich, US Euler, V Peltola, W Hirsch, W Lin, Y Berthezène, Y Ohba, Y Ohno, Y Ohno, Y Ohno, Y Ohno, Y Shao   +96 more
core   +1 more source

Genetic and environmental factors in interstitial lung diseases: current and future perspectives on early diagnosis of high-risk cohorts

Frontiers in Medicine, 2023
Within the wide scope of interstitial lung diseases (ILDs), familial pulmonary fibrosis (FPF) is being increasingly recognized as a specific entity, with earlier onset, faster progression, and suboptimal responses to immunosuppression.
Stefan Cristian Stanel, Stefan Cristian Stanel, Jack Callum, Pilar Rivera-Ortega   +3 more
doaj   +1 more source

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. [PDF]

, 2017
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life.
Collard, Harold R, Oldham, Justin M
core   +2 more sources

Drug Induced Interstitial Lung Disease [PDF]

The Open Respiratory Medicine Journal, 2012
With an increasing number of therapeutic drugs, the list of drugs that is responsible for severe pulmonary disease also grows. Many drugs have been associated with pulmonary complications of various types, including interstitial inflammation and fibrosis, bronchospasm, pulmonary edema, and pleural effusions. Drug-induced interstitial lung disease (DILD)
Schwaiblmair, Martin, Behr, Werner, Haeckel, Thomas, Märkl, Bruno, Foerg, Wolfgang, Berghaus, Thomas   +5 more
openaire   +3 more sources

Smoking-related interstitial lung disease [PDF]

, 2011
Cigarette smoking has a clear epidemiological association with lung diseases, characterised by chronic inflammation of both the bronchiolar and the interstitial lung compartments.
CERRI, Stefania, F. Luppi, RICHELDI, Luca, SPAGNOLO, Paolo   +3 more
core   +1 more source

Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity

Revista Portuguesa de Pneumologia (English Edition), 2017
Idiopathic pleuroparenchymal fibroelastosis (IPPFE) was recognized as a rare new entity. We report the case of a 63 years old female suffering from progressive dyspnea and dry cough for three years.
E.B. Boerner, U. Costabel, T.E. Wessendorf, D. Theegarten, F. Bonella   +4 more
doaj   +1 more source

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused

Frontiers in Medicine, 2020
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline.
Sachin Chaudhary, Bhupinder Natt, Christian Bime, Kenneth S. Knox, Kenneth S. Knox, Marilyn K. Glassberg   +5 more
doaj   +1 more source

Immune mechanisms in fibrotic pulmonary sarcoidosis

European Respiratory Review, 2022
Sarcoidosis is an immune-mediated disorder. Its immunopathology has been steadily mapped out over the past few decades. Despite this, the underpinning mechanisms for progressive fibrotic sarcoidosis is an almost uncharted area.
Praveen Weeratunga, David R. Moller, Ling-Pei Ho   +2 more
doaj   +1 more source